VIR Vir Biotechnology, Inc.
8-K Current Report
Filed: February 23, 2026
Health Care
Biological Products, (No Diagnostic Substances)Vir Biotechnology, Inc. (VIR) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 8.01: Other Events
- Item 1.01: Entry into a Material Definitive Agreement
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • Vir Bio receives $335M upfront/near-term: $240M cash + $75M equity + $20M milestone on manufacturing transfer (expected Q2-Q3 2027)
- • Astellas buys 7.24M shares at $10.36/share (~$75M), a 50% premium to 30-day VWAP — significant vote of confidence in VIR-5500
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced Feb 23, 2026
- • Detailed figures in Exhibit 99.2 of this filing
Item 8.01 · Other Events
- • VIR-5500 Phase 1 updated results announced Feb 23, 2026; oral presentation at ASCO GU Symposium Feb 26, 2026
- • VIR-5500 targets prostate cancer — early-stage data readout; Phase 1 results not indicative of later-stage outcomes
Other Vir Biotechnology, Inc. 8-K Filings
Get deeper insights on Vir Biotechnology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.